Organic anion transporters (OATs) are anion exchangers that transport small hydrophilic anions and diuretics, antibiotics, nonsteroidal anti-inflammatory drugs, antiviral nucleoside analogs, and antitumor drugs across membrane barriers of epithelia of diverse organs. Three OATs are present in human liver: OAT2, OAT5, and OAT7. Given that hepatocyte nuclear factor-1␣ (HNF-1␣) has previously been shown to regulate the expression of several hepatocellular transporter genes, we investigated whether the liver-specific human OAT genes are also regulated by HNF-1␣. Short interfering RNAs targeting HNF-1␣ reduced endogenous expression of OAT5 and OAT7, but not OAT2, in human liver-derived Huh7 cells. Luciferase reporter gene constructs containing the OAT5 (SLC22A10) and OAT7 (SLC22A9) promoter regions were transactivated by HNF-1␣ in HepG2 cells. Two putative HNF-1␣ binding elements in the proximal OAT5 promoter, located at nucleotides Ϫ68/ Ϫ56 and Ϫ173/Ϫ160, and one element in the OAT7 promoter, located at nucleotides Ϫ14/Ϫ2 relative to the transcription start site, were shown to bind HNF-1␣ in electromobility shift assays, and these promoter regions also interacted with HNF-1␣ in chromatin immunoprecipitation assays. A correlation between HNF-1␣ and OAT5 (r ϭ 0.134, P Ͻ 0.05) or OAT7 (r ϭ 0.461, P Ͻ 0.001) mRNA expression levels in surgical liver biopsies from 75 patients further supported an important role of HNF-1␣ in the regulation of OAT gene expression.
Introduction
Members of the solute carrier family SLC22 play a pivotal role in drug absorption and excretion. They share a predicted membrane topology consisting of twelve ␣-helical transmembrane domains (TMDs), a large glycosylated extracellular loop between TMDs 1 and 2, and a large intracellular loop between TMDs 6 and 7 with consensus sequences for phosphorylation (Burckhardt and Wolff, 2000; Koepsell and Endou, 2004) . The SLC22 protein family can be divided into subgroups according to transport mechanisms and substrates: the organic cation transporters, the organic carnitine transporters, and the organic anion transporters (OATs) (Koepsell and Endou, 2004) . Most members of the SLC22 family are polyspecific and transport multiple different substrates. OATs are anion exchangers that efficiently transport small hydrophilic anions. Furthermore, the transport substrates for OATs include anionic drugs, such as diuretics, antibiotics, nonsteroidal anti-inflammatory drugs, antiviral nucleoside analogs, and antitumor drugs (Sweet, 2005) .
Three OATs have been detected in human liver: OAT2 (gene symbol SLC22A7), OAT5 (SLC22A10), and OAT7 (SLC22A9) (Sun et al., 2001; Eraly and Nigam, 2002; Shin et al., 2007) . The rat Oat2 (Simonson et al., 1994) and the human OAT7 proteins (Shin et al., 2007) have been shown to be localized to the sinusoidal, but not bile canalicular, membranes of hepatocytes. Human OAT5 has so far been detected only by Northern blotting (Sun et al., 2001; Eraly and Nigam, 2002) , hence the subcellular localization of OAT5 remains elusive. The human OAT7 has been mapped to chromosomal region 11q13.1 (Shin et al., 2007) . The human OAT5 has been identified by a tBLASTn search of the expressed sequence tag database, and the OAT5 cDNA has been cloned by two groups (Sun et al., 2001; Eraly and Nigam, 2002 ). An updated sequence record for OAT5 (NM_001039752) was published by Taylor et al. (2006) . Human OAT5 has been mapped to chromosomal region 11q12.3. The mouse and rat Oat5 (Slc22a19) proteins have been shown to be exclusively expressed in kidneys (Youngblood and Sweet, 2004; Anzai et al., 2005) and are unlikely to be homologs of the human OAT5 protein (Koepsell and Endou, 2004) . Phylogenetic analysis on the entire SLC22 family in human, mouse, and rat has revealed no homologs for human OAT5 and OAT7 (Jacobsson et al., 2007) . Whereas the transport mechanisms for human OAT2 (Sun et al., 2001; Babu et al., 2002; Khamdang et al., 2003; Kobayashi et al., 2005) and OAT7 (Shin et al., 2007) have been characterized previously, transport substrates for human OAT5 are still under investigation.
Changes in the expression levels of OATs could influence the hepatic clearance of substrates from sinusoidal blood. Therefore, we addressed the question of whether transcriptional regulatory mechanisms that have been described previously for other OAT/Oat members (Popowski et al., 2005; Ahn and Nigam, 2009 ) are also involved in the regulation of human OAT2, OAT5, and OAT7 gene expression. A role for HNF-1␣ in regulating OAT1/Oat1 (Saji et al., 2008) and OAT3 (Kikuchi et al., 2006) gene expression has been reported previously. In this study, we show that HNF-1␣ is capable of increasing human OAT5 and OAT7 promoter activities, whereas endogenous knockdown of HNF-1␣ decreases OAT5 and OAT7 mRNA expression. In contrast, human OAT2 mRNA expression is unaffected by modulation of HNF-1␣ expression levels in hepatic cell lines. Consistent with this, we show in electromobility shift assays (EMSAs) and chromatin immunoprecipitation assays (ChIPs) that HNF-1␣ is capable of binding DNA elements in the proximal OAT5 and OAT7 promoters. Further support for the role of HNF-1␣ in regulation of OAT gene expression in human liver stems from the correlation between HNF-1␣ and OAT mRNA expression levels in human liver biopsies.
Materials and Methods

Chemicals. Deoxyadenosine 5Ј-[␣-
32 P]-triphosphate (6000 Ci/ mmol) was purchased from PerkinElmer Life and Analytical Sciences (Schwerzenbach, Switzerland). Restriction enzymes were from Roche Diagnostics (Rotkreuz, Switzerland), PuRe Taq Ready-To-Go PCR beads from GE Healthcare (Glattbrugg, Switzerland), and T4 DNA Ligase from Promega (Dü bendorf, Switzerland). The oligonucleotides were synthesized by Microsynth (Balgach, Switzerland). Other chemicals were purchased from Sigma-Aldrich (Buchs, Switzerland) unless stated otherwise.
Cells. The human hepatoma cell lines HepG2 (LGC Promochem, Wesel, Germany) and Huh7 (JCRB Cell Bank, Japan) were cultured in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 100 U/ml penicillin, and 100 g/ml streptomycin (Invitrogen, Basel, Switzerland). Cells were cultured at ϩ37°C in a humidified atmosphere containing 5% CO 2 . Fresh primary human hepatocytes were obtained from Lonza Verviers SPRL (Verviers, Belgium).
Transfection of Cells with siRNA. Huh7 cells were transfected on six-well plates at 70% confluence. Per transfection, 15 l of TransIT-TKO reagent (Mirus Bio LLC, LabForce) was mixed with 250 l of serum-free OptiMEM (Invitrogen), followed by addition of either the SMARTpool siRNAs targeting HNF-1␣ (Dharmacon, Lafayette, CO) or siCONTROL nontargeting siRNA 2 (Dharmacon) to a final concentration of 100 nM. After 15-min incubation at room temperature, the siRNA mixtures were added to the 1250 l of RPMI-1640 medium supplemented with 10% fetal bovine serum contained in each well. To knock down HNF-4␣ expression, Huh7 cells were transfected with siRNAs as described by Popowski et al. (2005) . Cells were harvested 24 h after transfection, and total cellular RNA and protein were extracted as described previously (Popowski et al., 2005) .
Isolation of RNA, Reverse Transcription, and Quantitative Real-Time PCR. Total RNAs from Huh7 cells or PHHs were isolated using the TRIzol reagent (Invitrogen). Total RNAs from 10 human tissues were derived from the Human Total RNA Master Panel (Clontech, Saint-Germain-en-Laye, France). RNAs were reverse-transcribed as described previously (Klein et al., 2009 ). Realtime PCR was performed on an 7900HT Fast Real-Time PCR system (Applied Biosystems, Rotkreuz, Switzerland) by using the TaqMan Gene Expression Assays for human HNF-1␣, HNF-4␣, OAT1, OAT2, OAT5, OAT7, OATP1B1, and OATP1B3 (Applied Biosystems). Constitutively expressed human ␤-actin was measured as an internal standard for sample normalization (Applied Biosystems). Isolation of total RNA from human liver biopsies and reverse transcription was described previously (Hahne et al., 2008) . Levels of HNF-1␣, OAT5, OAT7, and OAT2 mRNAs in liver biopsy material were quantified using TaqMan Gene Expression Assays as mentioned above and an iCycler iQ Multicolour Real-Time PCR Detector (Bio-Rad Laboratories, Hercules, CA). Constitutively expressed acidic ribosomal protein p0 mRNA was used as an internal standard for normalization of mRNA abundance. The relative mRNA levels were calculated by the comparative threshold cycle method.
Immunoblot Analysis. From siRNA-transfected Huh7 cells, 15 g of whole protein extracts were separated on 10% SDS polyacrylamide gels and electroblotted onto Hybond ECL nitrocellulose membranes (GE Healthcare). Membranes were blocked for 1 h in 5% (w/v) nonfat milk in PBS-T [0.1% (v/v) Tween 20 in phosphate-buffered saline]. After blocking, the membranes were probed with an antibody against HNF-1␣ (Santa Cruz Biotechnology Inc., Lab Force, Nunningen, Switzerland) or HNF-4␣ (Santa Cruz Biotechnology Inc.) at concentrations of 1 g/ml After three washes with nonfat milk/ PBS-T, the horseradish peroxidase-conjugated secondary goat antirabbit antibody (Pierce, Lausanne, Switzerland) was added at a concentration of 10 ng/ml in 5% (w/v) nonfat milk/PBS-T for 1 h. Blots were washed three times in PBS-T, followed by detection with the SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) and exposure on Hyperfilm ECL (GE Healthcare). To verify equal loading of the protein samples, the blots were stripped with Restore Western blot stripping solution (Pierce), reblocked, and reprobed for constitutively expressed Ku-70 antigen. The Ku-70 antibody (Santa Cruz Biotechnology Inc.) was used at a concentration of 50 ng/ml, and a horseradish peroxidase-conjugated rabbit anti-goat antibody (Dako Schweiz AG, Baar, Switzerland) was used as secondary antibody at a concentration of 167 ng/ml. Reporter Gene Constructs and Expression Vectors. Based on the genomic sequence (NC_000011) available in the U.S. National Center for Biotechnology Information database, fragments corresponding to the promoter regions of the human OAT5 and human OAT7 genes were PCR-amplified using the oligonucleotide primers shown in Table 1 and human genomic DNA (Clontech) as a template. PCR products were cloned into the pGEM-T vector and subcloned into the luciferase vector pGL3basic (Promega) to generate the OAT5 and OAT7 promoter reporter constructs. Point mutations were introduced into the OAT5(Ϫ265/ϩ187) construct and the OAT7(Ϫ73/ ϩ249) construct using the QuikChange site-directed mutagenesis kit (Stratagene, Basel, Switzerland) and oligonucleotides listed in Table  1 . The coding region of the human HNF-1␣ gene (NM_000545) was obtained through PCR amplification using oligonucleotide primers listed in Table 1 and human universal cDNA (Clontech) as a template. The PCR product was cloned into the pGEM-T vector and subcloned into the pcDNA3.1(Ϫ) vector (Invitrogen). The sequences of all constructs were verified by DNA sequencing (Microsynth).
Transient Transfections and Reporter Assays. HepG2 cells were seeded on 48-well plates at a density of 10 5 cells/well and cotransfected with 400 ng of the luciferase reporter constructs and 200 ng of the expression plasmids, using FuGENE HD reagent (Roche Diagnostics), at a ratio of 3 l of FuGENE HD per 1 g of DNA. To normalize the amount of DNA transfected, the pcDNA3.1(Ϫ) vector was added where appropriate. To control for transfection efficiency, 100 ng of the Renilla reniformis luciferase (phRG-TK) reporter plasmid (Promega) were cotransfected. Cells were harvested 36 h after transfection, and luciferase activities were determined using the Dual Luciferase Assay System (Promega) by using a Luminoskan Ascent microplate luminometer (Thermo Fisher Scientific, Wohlen, Switzerland). Reporter activities obtained for the empty pGL3basic corresponding to each test condition, as well as for the test construct containing the test promoter in the control conditions, were set to 1 and fold activities are shown relative to this.
Electrophoretic Mobility Shift Assays. EMSA binding reactions were performed as described previously (Klein et al., 2009) . Oligonucleotides used in EMSAs (Table 1) were designed to have a 5Ј-AGCT overhang in the top strand and a 5Ј-GATC overhang in the bottom strand when annealed, allowing radioactive labeling by fill-in reactions. Two microliters of in vitro-translated HNF-1␣ (Tnt-HNF-1␣) or 10 g of nuclear extract extracted from HepG2 cells using the NE-PER kit (Pierce) were used for DNA-binding reactions. In supershift experiments, 1 g of HNF-1␣ antibody (Santa Cruz Biotechnology Inc.) was added to the extracts 1 h before the radioactive probe and incubated at ϩ 4°C. Immediately after the binding reactions, the samples were loaded onto pre-electrophoresed 5% (acrylamide/bis 30:1) native acrylamide gels and run at 200 V in 0.5ϫ Tris borate-EDTA for 1.5 h. The gels were fixed in 10% (v/v) acetic acid for 10 min, dried onto DEAE cellulose paper (DE81; Whatman GmbH, Dassel, Germany) under vacuum, and exposed to Kodak BioMax MR-1 films (Sigma-Aldrich) at Ϫ80°C.
Chromatin Immunoprecipitation Assays. HepG2 cells were grown on 10-cm plates to 80% confluence, harvested, and processed through chromatin immunoprecipitation using the ChIP-IT Express kit (Active Motif, Rixensart, Belgium). Shearing of chromatin was achieved by 10 pulses of sonication with 30-s pauses on ice between each pulse, using the Branson Digital Sonifier (Branson Ultrasonics, Danbury, CT) at power setting 25%. Aliquots of sheared chromatin were incubated either without antibody, with 1 g of negative control mouse IgG1 (Dako Denmark A/S, Glostrup, Denmark), or with 1 g of anti-HNF-1␣ antibody (Santa Cruz Biotechnology). Two amplicons were assayed for immunoprecipitation test, by using PuRe Taq Ready-To-Go PCR beads (GE Healthcare) and the oligonucleotide primers listed in Table 1 , comprising HNF-1␣ target regions in OAT5, OAT7, and OATP1B1 promoters as well as nontarget regions located within intron 1 of each gene. After 40 cycles, 10 l of each PCR product were resolved on 2% agarose gels and detected with SYBR Safe DNA Gel Stain (Invitrogen). Sizes of PCR products were as follows: OAT5 promoter, 253 bp; OAT5 intron, 311 bp; OAT7 promoter, 208 bp; OAT7 intron, 272 bp; OATP1B1 promoter, 301 bp; OATP1B1 intron, 264 bp.
Study Subjects. Our study subjects included 75 obese patients without type 2 diabetes who underwent weight-reducing surgery. Tissue biopsies obtained from liver during surgery were collected in RNAlater (Ambion, Austin, TX). All study subjects provided informed consent, and study protocols were approved by the local ethics committee.
Statistical Analysis. All quantitative data are reported as means Ϯ S.D. Differences between experimental groups were analyzed by unpaired t test (siRNA experiments) and one-way analysis 
Results
Expression Profiling of OAT mRNAs in Human Tissues. The presence of OAT2, OAT5, and OAT7 mRNA in the human liver has previously been demonstrated by Northern blotting (Sun et al., 2001; Eraly and Nigam, 2002; Shin et al., 2007) . We first verified this more quantitatively by performing TaqMan real-time PCR analysis on their expression, as well as that of OAT1, on RNA samples derived from 10 human tissues and primary human hepatocytes (Table 2) . We confirmed that OAT2, OAT5, and OAT7 mRNAs, but not OAT1 mRNA, are abundantly expressed in the liver and primary human hepatocytes. As reported previously (Sun et al., 2001) , OAT2, together with OAT1, was also detected in the kidney. None of the other nine tissues examined expressed quantifiable levels of the four OAT mRNAs. Short Interfering RNA-Mediated Knockdown of Endogenous HNF-1␣ Expression Results in Reduced mRNA Expression of Human OAT5 and OAT7. We next studied whether the three human liver OAT genes are regulated by similar mechanisms. A role for HNF-1␣ in regulating OAT/Oat gene expression was previously suggested (Kikuchi et al., 2006; Saji et al., 2008) . The liver-specific transporter genes OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) have been shown to be regulated by HNF-1␣ (Jung et al., 2001) . To study the role of HNF-1␣ in the regulation of OATs, we reduced the endogenous HNF-1␣ expression by transfecting Huh7 cells with specific siRNAs against HNF-1␣. To control for any nonspecific effects, we transfected an equal amount of control siRNAs not known to target any human genes. As shown in Fig. 1 , by transfecting HNF-1␣-specific siRNA, levels of both HNF-1␣ mRNA (Fig.  1A) and HNF-1␣ protein (Fig. 1B) were significantly reduced. This reduction was accompanied by decreased mRNA levels for both OAT5 and OAT7. In contrast, OAT2 mRNA expression was not affected by reduced HNF-1␣ expression (Fig.  1A) . In support of the role for HNF-1␣ in the regulation of OAT5 and OAT7 expression, the mRNA expression levels of the known target genes for HNF-1␣, OATP1B1 and OATP1B3 (Jung et al., 2001 ), were similarly suppressed by the HNF-1␣ knockdown (Fig. 1A) . These data suggest that HNF-1␣ is involved in maintaining the baseline expression of OAT5 and OAT7, but not OAT2, in human liver-derived cells. Because the gene encoding HNF-1␣ itself is known to be regulated by HNF-4␣ (Jung and Kullak-Ublick, 2003), we studied the effects of HNF-4␣ siRNA on HNF-1␣ expression and on the expression of its newly identified target genes OAT5 and OAT7 (Fig. 1, C and D) . Levels of both HNF-4␣ mRNA and protein were efficiently reduced by the siRNAs, as was the mRNA expression level of the direct HNF-4␣ target gene, OAT2 (Popowski et al., 2005) . As expected, there was also a more modest, yet significant, suppression of mRNA expression of HNF-1␣, as well as of OAT5 and OAT7, upon suppression of HNF-4␣ expression. In promoter luciferase studies, we observed no activating effect by HNF-4␣ on OAT5 and OAT7 promoters (data not shown), and we thus propose that the HNF-4␣ siRNAs lead to down-regulation of OAT5 and OAT7 via a suppressive effect on their direct transactivator HNF-1␣.
HNF-1␣ Transactivates the OAT5 and OAT7 Promoters. To further study the effects of HNF-1␣ on OAT5 and OAT7 promoter activities HepG2 cells were cotransfected with reporter-linked OAT5(Ϫ764/ϩ187) and OAT7(Ϫ848/ ϩ249) promoter constructs, either with or without an expression plasmid for HNF-1␣. As shown in Fig. 2 , overexpression of HNF-1␣ significantly transactivated both the OAT5 and OAT7 promoters. Next, a series of 5Ј deletions of the OAT5(Ϫ764/ϩ187) and the OAT7(Ϫ848/ϩ249) promoter constructs were constructed to identify the promoter regions that account for the transactivation by HNF-1␣. Deletion of the region upstream of Ϫ265 bp had no effect on HNF-1␣-mediated induction of OAT5 promoter activity, whereas a further deletion of the promoter region to position Ϫ41 bp resulted in the loss of HNF-1␣-mediated transactivation ( Fig.  2A) . Whereas the OAT7(Ϫ848/ϩ249) promoter construct showed approximately 2-fold induction upon cotransfection of the HNF-1␣ expression plasmid, deletion of the genomic region upstream of Ϫ73 resulted in an increase in this effect (Fig. 2B) , suggesting that there are promoter elements between Ϫ848 and Ϫ73 that are capable of attenuating the effect of HNF-1␣ on the OAT7 promoter. Further deletion from Ϫ73 to ϩ16 of the OAT7 promoter led to a loss of HNF-1␣-mediated transactivation. In summary, the HNF-1␣-responsive regions were located between Ϫ265 and Ϫ41 bp in the OAT5 promoter and between Ϫ73 and ϩ16 bp in the OAT7 promoter, leading us to focus our subsequent experiments on these promoter regions.
Identification of Putative HNF-1␣ Response Elements in the OAT5 and OAT7 Promoters. An in silico analysis was carried out on the OAT5 promoter sequence between nucleotides Ϫ265 and Ϫ41 and on the OAT7 promoter sequence between nucleotides Ϫ73 and ϩ16 in an attempt to identify potential HNF-1␣ binding sites. Web-based software tools for locating possible transcription factor binding sites, such as TESS (Schug, 2008) , MatInspector Software (Cartharius et al., 2005) , and PROMO (Messeguer et al., 2002) could not identify any putative HNF-1␣ binding sites within these promoter regions. Visual inspection revealed the existence of two potential HNF-1␣ binding sites located between nucleotides Ϫ173 and Ϫ160 and nucleotides Ϫ68 and Ϫ56 in the OAT5 promoter sequence. The site Ϫ173/Ϫ160 differs from the HNF-1␣ consensus sequence (Mendel and Crabtree, 1991) by 5 bp, whereas the Ϫ68/Ϫ56 site contains four divergences from the consensus sequence (Fig. 3A) . One potential HNF-1␣ binding site in the OAT7 promoter was identified by aligning the OAT5(Ϫ265/Ϫ41) promoter sequence with the OAT7(Ϫ73/ ϩ81) promoter sequence (Fig. 3B ) using the EMBOSS pairwise alignment algorithms (http://www.ebi.ac.uk/Tools/emboss/align/ index.html). The potential HNF-1␣ binding site in the proximal OAT7 promoter is located between nucleotides Ϫ14/Ϫ2 and bears a high degree of similarity to the OAT5 Ϫ68/Ϫ56 binding site. The OAT7 Ϫ14/Ϫ2 site differs from the HNF-1␣ consensus sequence by 5 bp (Fig. 3A) . 
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Two HNF-1␣ Binding Sites within the OAT5 Promoter and One Site in the OAT7 Promoter Are Functional. To investigate the role of the identified putative HNF-1␣ binding sites in HNF-1␣-mediated transactivation of the OAT5 and OAT7 promoters, these DNA elements were mutated by site-directed mutagenesis, and cotransfection experiments were performed. The transactivation by HNF-1␣ was significantly reduced in cotransfections upon mutating the OAT5(Ϫ173/Ϫ160) and OAT5(Ϫ68/Ϫ56) motifs, compared with the wild-type OAT5(Ϫ265/ϩ187) reporter construct (Fig. 4A) . Simultaneous disruption of both elements resulted in a complete loss of HNF-1␣-mediated induction of OAT5 promoter activity. Mutagenesis of the single binding site (Ϫ14/Ϫ2) in the OAT7(Ϫ73/ϩ249) promoter construct was sufficient to completely disrupt HNF-1␣-mediated induction of OAT7 promoter activity (Fig. 4B ). These results demonstrate that all putative HNF-1␣ response elements identified by in silico Fig. 3 . Identification of putative HNF-1␣ elements within the human OAT5 and OAT7 promoters. A, in the top row, the consensus sequence of a HNF-1␣ response element is shown. Sequence and location relative to the transcriptional start site of the potential HNF-1␣ response elements of the OAT5 and OAT7 promoters are shown. Nucleotides mutated for experiments in Figs. 4 and 5 are shown in bold. B, proximal promoter sequences of OAT5 and OAT7 were analyzed pairwise. The OAT5(Ϫ68/ Ϫ56) and the OAT7(Ϫ14/Ϫ2) HNF-1␣ elements (box) show a high degree (76.9%) of similarity. Fig. 4 . Two HNF-1␣ elements within the human OAT5 promoter and one element in the human OAT7 promoter are functional. HepG2 cells were cotransfected with reporter-linked OAT5 promoter construct Ϫ265/ϩ187 (A) and OAT7 promoter construct Ϫ73/ϩ249 (B), as well as with the promoterless reporter vector pGL3basic. HNF-1␣ elements in the promoter constructs were mutated (black boxes) by site-directed mutagenesis. With each construct, either a cytomegalovirus promoter-driven expression plasmid for HNF-1␣ or an empty pcDNA3.1(Ϫ) vector (control) was cotransfected. Relative luciferase activities obtained for pcDNA3.1(Ϫ)-transfected cells are set to 1, and the fold activities in other test conditions are shown relative to these. n.s., not significant. ‫,ءء‬ p Ͻ 0.01. ‫ءءء‬ p Ͻ 0.001. Fig. 5 . HNF-1␣ specifically binds to two elements within the OAT5 promoter and one element in the OAT7 promoter. EMSAs were performed using in vitro translated HNF-1␣ (Tnt-HNF-1␣) (A) or HepG2 nuclear extracts (B) and the OAT5 and OAT7 sequences containing the wild-type (WT) or mutated (mut) HNF-1␣ elements, or HNF-1␣ consensus binding motif, as radiolabeled probes. Numbers indicate the position of the HNF-1␣ elements within oligonucleotide probes. To identify protein-DNA complexes specifically formed between HNF-1␣ and the radiolabeled probes, samples preincubated with HNF-1␣ antibodies were included as indicated. Fig. 6 . HNF-1␣ interacts with the HNF-1␣-responsive regions of the OAT5, OAT7, and OATP1B1 promoters within HepG2 cells. ChIP samples were incubated either without antibodies, with negative control mouse IgG, or with anti-HNF-1␣ antibodies. Two amplicons for each gene were assayed for using primers flanking the HNF-1␣ target regions in the OAT5, OAT7, and OATP1B1 promoters as well as primers derived from nontarget regions located within intron 1 of each gene. HNF-1␣-specific antibody was efficient in precipitating the promoter regions of OAT5 (A), OAT7 (B), and OATP1B1 (C), whereas no significant signal was obtained for the intronic regions of the three genes. 1, input; 2, no antibody; 3, mouse IgG; 4, anti-HNF-1␣ antibody.
analysis within the OAT5 and OAT7 promoter regions are functional.
HNF-1␣ Binds to Two Elements within the Proximal OAT5 Promoter and One Element in the OAT7 Promoter. To confirm that HNF-1␣ is capable of directly binding to the elements in the OAT5 and OAT7 promoters, EMSAs were performed using wild-type and mutated double-stranded oligonucleotides comprising the OAT5(Ϫ68/Ϫ56), the OAT5(Ϫ173/ Ϫ160), and the OAT7(Ϫ14/Ϫ2) HNF-1␣ binding sites and in vitro translated HNF-1␣ protein (Fig. 5A ). HNF-1␣ was able to form complexes with all three wild-type probes. The complexes were disrupted after addition of HNF-1␣ antibodies. No complex formation was found with mutated OAT5 and OAT7 oligonucleotides. Likewise, two complexes of similar mobility to those DNA-protein complexes forming on the HNF-1␣ consensus motif could form on all three wild-type, but not mutant, OAT probes, when these were incubated with nuclear extracts derived from HepG2 cells (Fig. 5B ).
These endogenous complexes did not form on the mutant OAT probes, and the addition of the HNF-1␣ antibody disrupted the formation of these complexes. The two complexes are likely to be two differentially modified (e.g., phosphorylation) isoforms of HNF-1␣. These data indicate that HNF-1␣ is capable of binding to both HNF-1␣-responsive elements in the proximal OAT5 and the single element in the proximal OAT7 promoter sequences in vitro.
HNF-1␣ Interacts with Its Responsive Regions in the OAT5 and OAT7 Promoters within Living Cells. To investigate whether there is a direct interaction between HNF-1␣ and the OAT5 and the OAT7 promoter regions within living cells, we performed ChIP analysis in HepG2 cells. Proteins were cross-linked to DNA in vivo using formaldehyde, the cells were lysed and the chromatin was sheared into fragments of 300 to 600 bp. Next, immunoprecipitations were performed using an anti-HNF-1␣ antibody. The anti-HNF-1␣ antibody efficiently precipitated OAT5 molpharm.aspetjournals.org (Fig. 6A) and OAT7 (Fig. 6B) promoter regions containing the HNF-1␣ response elements, whereas the nonspecific mouse IgG antibody did not yield a precipitate. As a positive control, we performed chromatin immunoprecipitations on the known direct target for HNF-1␣ (i.e., OATP1B1) using the same samples. Like OAT5 and OAT7, the HNF-1␣ antibody, but not the negative control antibody, precipitated the HNF-1␣-responsive region of the OATP1B1 gene (Fig. 6C) . As an additional specificity control, we amplified short regions located in the first introns of the OAT5, OAT7, and OATP1B1 genes, using the same ChIP samples as PCR templates. The anti-HNF-1␣ antibody was not able to efficiently precipitate the intronic regions from any of the three genes (Fig. 6, A-C) . These results confirm that HNF-1␣ specifically interacts with the regions of the OAT5 and OAT7 promoters containing the identified HNF-1␣ response elements within living cells.
HNF-1␣ mRNA Expression Correlates with OAT mRNA Levels in Human Liver Samples. To study the relevance of HNF-1␣ in the regulation of hepatic OAT5 and OAT7 expression in vivo, we measured HNF-1␣, OAT5, and OAT7 mRNA levels in 75 surgically resected human liver samples by quantitative TaqMan PCR. Using multiple regression models, we found a borderline association of HNF-1␣ and OAT5 mRNA expression (Fig. 7A ) and a strong correlation between HNF-1␣ and OAT7 mRNA levels (Fig. 7B) . Furthermore, we measured the OAT2 mRNA levels in the same samples. Surprisingly, the OAT2 mRNA levels were also strongly correlated with HNF-1␣ expression levels (Fig. 7C) , even if we have found no evidence that the OAT2 promoter is a direct target for HNF-1␣. Significant associations between OAT mRNA expression levels were also found after adjusting the results for sex, age, body mass index, and homeostasis model assessment-insulin resistance (Table 3) .
Discussion
Hepatic drug uptake from the sinusoidal blood and excretion into bile are important functions of the liver. OATs are located at the barrier epithelia of various tissues, where they mediate absorption and excretion of a range of metabolites, signaling molecules, and drugs (Ahn and Nigam, 2009) . Three members of the OAT family have been detected at the mRNA level, in human liver: OAT2 (SLC22A7), OAT5 (SLC22A10), and OAT7 (SLC22A9) (Sun et al., 2001; Eraly and Nigam, 2002; Shin et al., 2007) . Transport properties of OAT2, which is expressed at high levels in the liver and to a lesser extent in kidneys, have been studied in detail (Sun et al., 2001; Babu et al., 2002; Khamdang et al., 2003; Kobayashi et al., 2005) . Human OAT7 exhibits a narrow substrate selectivity compared with other OAT family members and was shown to transport estrone sulfate and dehydroepiandrosterone sulfate in exchange for butyrate (Shin et al., 2007) . Human OAT5 mRNA is detectable only in liver (Sun et al., 2001; Eraly and Nigam, 2002) . OAT5 transport substrates are still under investigation. Changes in the expression levels of OATs could influence the hepatic clearance of transport substrates from sinusoidal blood.
A role for HNF-1␣ in regulating SLC22 gene expression was suggested by studies in HNF-1␣ knockout mice that showed altered expression of several transporter genes in liver, kidney, and duodenum compared with wild-type animals (Shih et al., 2001; Maher et al., 2006) . HNF-1␣ plays a prominent role in the regulation of a wide variety of hepatocyte-specific genes, although it is also expressed in other tissues. The HNF-1␣ consensus DNA-binding site is an inverted palindrome with which HNF-1␣ interacts as a homodimer (Mendel and Crabtree, 1991) . Human and mouse OAT1/Oat1 (Saji et al., 2008) , OAT3 (Kikuchi et al., 2006) , and URAT1/Urat1 (Kikuchi et al., 2007) promoter activities have been shown to be regulated by HNF-1␣ and HNF-1␤. In addition to certain members of the SLC22 family, promoter regions of other human SLC transporter genes, such as SLCO1B1, SLCO1B3 (Jung et al., 2001) , AE2 anion exchanger (SLC4A2) (Malumbres et al., 2003) , Na ϩ -glucose cotransporter gene SGLT1 (SLC5A1) (Martín et al., 2000) , type I Na ϩ -phosphate cotransporter (NPT1; SLC17A1) (Soumounou et al., 2001) , concentrative nucleoside transporter 2 (CNT2; SLC28A2) (Yee et al., 2009) , and sodium-dependent vitamin C transporter protein 1 (SVCT1; SLC23A1) (Michels and Hagen, 2009 ) have been shown to be regulated by HNF-1␣. HNF-1␣ variants containing common polymorphisms that are associated with increased type 2 diabetes risk exhibit decreased transactivation potential on glucose transporter 2 (SLC2A2) promoter activity (Holmkvist et al., 2006) . The human OAT1 (Ogasawara et al., 2007) and OAT2 (Popowski et al., 2005) promoter activities are increased by another liver-enriched transcription factor: HNF-4␣. We have not been able to detect a role of HNF-4␣ as a direct regulator of the human OAT5 and OAT7 promoters (data not shown), although we note that siRNA-mediated knockdown of HNF-4␣ in liver-derived cells resulted in a modest, but significant, suppression of OAT5 and OAT7 mRNA levels, probably via suppression of HNF-1␣ expression.
In this study we showed that the human OAT5 and human OAT7 transporter genes are also regulated by HNF-1␣. We identified two functional binding elements in the proximal OAT5 promoter and one element in the OAT7 promoter that are essential for the HNF-1␣-mediated increase in promoter activities in liver-derived cells. Mutagenesis of both elements in the OAT5 promoter resulted in a complete loss of HNF-1␣-mediated transactivation, whereas disruption of either single element led to slightly decreased transactivation of OAT5 promoter activity. Mutagenesis of the single binding element in the OAT7 promoter was sufficient to disrupt HNF-1␣-mediated transactivation of the OAT7 promoter. We showed in EMSAs and ChIPs that HNF-1␣ directly binds to the identified promoter elements both in vitro and within living cells. A correlation between HNF-1␣ and OAT5 or OAT7 mRNA expression levels in human liver tissue further supports the important role of HNF-1␣ in the regulation of OAT gene expression. We also observed a correlation be- tween HNF-1␣ levels and OAT2 mRNA levels in human liver tissue, although no evidence that HNF-1␣ regulates the OAT2 promoter via direct interactions has been obtained from HNF-1␣ siRNA experiments (Fig. 1A) or promoter-luciferase studies. This suggests further complexity of the regulation of the OAT transporter genes and indicates that HNF-1␣ may be an important determinant of hepatic OAT expression by both direct and indirect mechanisms. Significant correlations between OAT5, OAT7, and OAT2 mRNA levels were also found, suggesting common regulatory mechanisms between the OAT genes in human liver in vivo. We note that the patient cohort employed here is highly obese, which may be considered a potential confounding factor. In summary, these data emphasize the central role of HNF-1␣ in regulating human SLC22A transporter gene expression. It will be of interest to further investigate whether OAT5 and OAT7 gene expression is altered via disturbed HNF-1␣ signaling in disease states, such as diabetes.
